… with erlotinib plus bevacizumab compared with erlotinib … -positive (EGFR+) non-small-cell
lung cancer (NSCLC). Here … assess the impact of erlotinib plus bevacizumab treatment in …

… Low-dose erlotinib appears to be safe and effective in elderly or frail patients
withEGFRmutation–positive non–small cell lung cancer and can be a valid treatment option. …

… erlotinib with Teliso-V in the c-Met high EGFRm population demonstrated an ORR of 32.1%;
suggesting that the addition of erlotinib improved treatment … -V combined with erlotinib (15). …

… Lung carcinoma has the highest mortality rates among all types of cancers, of which non-small-cell
lung cancer … Despite vast advances in NSCLC treatments including surgery, radiation …

… In the present study, patients treated with erlotinib had a trend toward better clinical ORR, …
Furthermore, patients treated with erlotinib had a significantly greater reduction in tumor …

… Non-small cell lung cancer (NSCLC) has a poor prognosis despite conventional treatments
of … In particular, combining erlotinib with the VEGF antibody bevacizumab has therapeutic …

… Therefore, we aimed to compare bevacizumab–erlotinib versus erlotinib alone in the
treatment of advanced EGFR-mutant metastatic NSCLC in the phase 3 trial NEJ026. The interim …

… With erlotinib, a single-nucleotide polymorphism mutation in UBXN11 was associated with
… erlotinib compared with chemotherapy in R0 stage III EGFR+ non–small-cell lung cancer. …

… is the first prospective trial to evaluate erlotinib as a systemic treatment in this setting. …
erlotinib treatment is active for LM. Our findings suggest that erlotinib could be a useful treatment …

… aimed to compare erlotinib (E) and etoposide/cisplatin (EP) with concurrent radiation therapy
(RT) for patients with stage IIIA/B unresectable advanced non-small cell lung cancer with …